Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.
Study Design
- Study Type
- Randomized Controlled Trial
- Population
- Diabetes patients
- Intervention
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. None
- Comparator
- None
- Primary Outcome
- consequences of an increased intake of fish and plant-based omega-3 fatty aci...
- Effect Direction
- Positive
- Risk of Bias
- Unclear
Abstract
BACKGROUND: Cardiovascular diseases (CVDs) are defined as conditions involving decreased blood flow to the heart that can lead to heart attacks, stroke or other disorders. CVDs are a common cause of death in low- and middle-income countries. In South Africa (SA) in particular, CVD is the leading cause of death after HIV/AIDS, responsible for 1 in 6 deaths. CVD risk factors include unhealthy diets, hypertension, obesity, high cholesterol levels and diabetes. Omega-3 fatty acids may have a protective role in the risk of developing heart disease. OBJECTIVES: To evaluate the consequences of an increased intake of fish and plant-based omega-3 fatty acids on the risk of CVD mortality and events. METHODS: The inclusion criteria for this review were randomised controlled trials (RCTs) lasting at least 12 months, which investigated men and women aged ≥18 years. These participants had to be at any risk of CVD while receiving dietary supplements and an advised diet to promote the intake of omega-3. This diet included oily fish, fish oils and seeds rich in omega-3. Comparisons with the interventions included the participants' usual diet, no advice, no supplements, placebo or lower-dose omega-3. The review evaluated the effectiveness of these interventions on primary (e.g. CVD deaths and events), secondary (e.g. major adverse cerebrovascular or CVD events, body weight and other adiposity measures, and lipids) and tertiary (e.g. blood pressure and side-effects) outcomes. RESULTS: Evidence from this review indicates that increasing the intake of long-chain omega-3 fatty acids (LCn3) or alpha-linolenic acid (ALA) probably has little or no effect on all-cause CVD or coronary heart disease mortality. Evidence was of moderate certainty, except for all-cause mortality, where there was a high certainty. CONCLUSIONS: According to moderate- to high-certainty evidence, short-chain fatty acids and LCn3 have little or no effect on mortality or cardiovascular health. However, omega-3 ALA slightly reduces the risk of CVD events and arrhythmias.
TL;DR
Evidence from this review indicates that increasing the intake of long-chain omega-3 fatty acids (LCn3) or alpha-linolenic acid (ALA) probably has little or no effect on all-cause CVD or coronary heart disease mortality, but omega- 3 ALA slightly reduces the risk of CVD events and arrhythmias.
Used In Evidence Reviews
Similar Papers
Pharmacological research · 1999
Health benefits of docosahexaenoic acid (DHA).
Circulation · 2010
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Contemporary clinical trials · 2012
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
Journal of clinical hypertension (Greenwich, Conn.) · 2011
Role of mercury toxicity in hypertension, cardiovascular disease, and stroke.
Progress in neuro-psychopharmacology & biological psychiatry · 2008
The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study.
The Cochrane database of systematic reviews · 2007